ICER releases Draft Evidence Report on multiple myeloma therapies News item 20 February 2021 Pages: 1 - 1
Are pathogen-reduction technologies in blood transfusion worth the extra cost? Review 20 February 2021 Pages: 3 - 3
Assessing value of screening for latent TB infection among migrants in Sweden Clinical study 20 February 2021 Pages: 4 - 4
Breast cancer surgery creates financial burden in US patients Clinical study 20 February 2021 Pages: 5 - 5
Cabotegravir + rilpivirine for HIV-1 treatment: improved adherence, better outcomes, lower cost Clinical study 20 February 2021 Pages: 7 - 7
Cemented and hybrid fixation seem to be most cost-effective in total hip arthroplasty Clinical study 20 February 2021 Pages: 9 - 9
Cognitive behavioural therapy for prevention of chronic widespread pain: QOL benefits at acceptable cost Clinical study 20 February 2021 Pages: 10 - 10
Contrast-enhanced ultrasound of cystic renal lesions cost effective Clinical study 20 February 2021 Pages: 11 - 11
Crowdsourcing to assess financial toxicity in gynaecological cancer Clinical study 20 February 2021 Pages: 12 - 12
Durvalumab not cost effective for first-line treatment of advanced SCLC Clinical study 20 February 2021 Pages: 13 - 13
Expanding MRSA prevention initiative cost effective in US Clinical study 20 February 2021 Pages: 14 - 14
FLUZONE High Dose cost effective in adults aged ≥65 years Clinical study 20 February 2021 Pages: 15 - 15
High levels of cost-sharing during PARP inhibitor treatment for ovarian cancer in the US Clinical study 20 February 2021 Pages: 16 - 16
Ibalizumab cost effective for multidrug-resistant HIV-1 infection in USA? Clinical study 20 February 2021 Pages: 17 - 17
Infections caused by multidrug-resistant bacteria high burden in the US Clinical study 20 February 2021 Pages: 18 - 18
Is cemiplimab cost effective in advanced cutaneous squamous cell carcinoma? Clinical study 20 February 2021 Pages: 19 - 19
Laparoscopy cost effective in untreated advanced ovarian cancer Clinical study 20 February 2021 Pages: 20 - 20
Large economic burden of spinal muscular atrophy: review of current evidence Review 20 February 2021 Pages: 22 - 22
Low-value diagnostic imaging: burden on children and Medicaid programmes in the US Clinical study 20 February 2021 Pages: 23 - 23
Preimplantation genetic testing for aneuploidy cost effective? Clinical study 20 February 2021 Pages: 24 - 24
Reviewing cost-effectiveness evidence of varicella zoster virus vaccination strategies Review 20 February 2021 Pages: 25 - 25
Risk-based breast cancer screening that incorporates breast density saves more lives at acceptable cost Clinical study 20 February 2021 Pages: 26 - 26
Should a rotavirus vaccine be included in the national immunisation programme in Thailand? Clinical study 20 February 2021 Pages: 27 - 27
Systemic therapy for mantle-cell lymphoma: frequent costly AEs Clinical study 20 February 2021 Pages: 28 - 28
Using molecular testing/whole-genome sequencing for TB diagnosis cost effective in low-burden setting Non-clinical study 20 February 2021 Pages: 29 - 29
Whole-genome sequencing of multidrug-resistant bacteria cost saving for hospitals Non-clinical study 20 February 2021 Pages: 30 - 30
NICE approves pembolizumab combination for non-squamous NSCLC News item 20 February 2021 Pages: 31 - 31
NICE launches public consultation on proposed guidance changes Clinical study 20 February 2021 Pages: 32 - 32
NICE recommends nivolumab for melanoma in final draft guidance News item 20 February 2021 Pages: 34 - 34